Skip to main content
FDA clears IND for VistaGen's Parkinson's drug
1/31/2020

VistaGen Therapeutics' investigational new drug application for its N-methyl-D-aspartate receptor glycine site antagonist candidate AV-101 gained the FDA's clearance, allowing the company to advance plans for a midstage trial to assess the drug in patients with Parkinson's disease who are being given levodopa-based therapy.

Full Story: